drug
mirvetuximab soravtansine
Marketedupdated 6mo agoby ImmunoGen Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying mirvetuximab soravtansine
- phase2A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
- phase2A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
- phase3AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
- phase2Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- phase2A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression
- phase2An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
- phase3Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- phase2Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers
News(7)
- From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data dramaEvery ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly anticipated phase 3 data for Moderna and Merck & Co.’s cancer vaccine were leaked…fiercebiotech · 2d ago
- Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trialExtending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.biospace · 3d ago
- #ESMO26: AstraZeneca eyes Keytruda's Padcev spot; Lilly's ADC takes on Elahere; Nubeqa targets earlier prostate cancerMADRID — It's been estimated that almost 40,000 delegates will be attending this year's ESMO congress over five days in Madrid. And on Saturday, they have new data to review from AstraZeneca, Eli L…endpoints · 5d ago
- ESMO: Genmab posts phase 3 win for Elahere rival, ahead of ‘very interesting’ data from Merus buyoutGenmab may have arrived in Spain with updated data from a pair of phase 2 studies from the main prize of its Merus buyout, but the company had bigger news to share.fiercebiotech · 5d ago
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 9d ago
- ESMO: Lilly touts 79% ADC response rate in competitive ovarian cancer spaceEli Lilly has shared phase 1 data on an antibody-drug conjugate in platinum-sensitive ovarian cancer, shedding light on the company’s chances of competing for a market targeted by rivals including…fiercebiotech · 10d ago
- Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s ElahereGenmab has linked an antibody-drug conjugate to a median progression-free survival of 9.5 months, leading TD Cowen analysts to hail the asset as “clearly superior” to AbbVie’s Elahere.fiercebiotech · 24d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that